Gene correction therapies for rare metabolic diseases
Explore Our Research
Our Mission
Driving innovation in genetic medicine to transform patient lives:
In pediatric metabolic diseases effective treatment options are still limited. Many of these patients suffer from individually rare diseases. Despite their uniqueness, these conditions share a common foundation: a genetic mechanism driving the disease. Our mission is to develop advanced gene-editing therapies, such as base editing and prime editing, to address this underlying cause.
Fuchs' Laboratory Publications
Research Pipeline
Kyra
Fuchs' Laboratory Publications
Our Publications
Experience the advantages for rare genetic conditions: transformative solutions, maximized treatment potential, and streamlined delivery methods
Mutation-specific reporter for optimization and enrichment of prime editingSchene et al., 2022, Nature Communications.
Prime editing for functional repair in patient-derived disease models Schene et al., 2020, Nature Communications
The potential and limitations of intrahepatic cholangiocyte organoids to study inborn errors of metabolism Lehmann et al., 2021, JIMD
Our Partners, Grants, and Collaborations
Collaborating with leading partners to deliver cutting-edge therapies to patients. Interested in collaborating with us?
Join our Laboratory
Researchers in our Lab
Jose Castro
PhD Candidate
As a PhD candidate, I'm not just reading about the future of therapeutics; I'm actively shaping it through our advanced gene correction research.
Eva
MSc Student
Every experiment I conduct with virus-like particles feels like I'm one step closer to a world where genetic diseases are a thing of the past.
Martijn
Postdoctoral Researcher
My postdoc research dives into the intricacies of gene editing, and it's exhilarating to contribute to technology that may one day cure genetic disorders.
Careers
We are a dynamic team with members from various scientific backgrounds and are always looking for enthusiastic new members. Interested in joining us? Connect with our Principal Investigator, Sabine Fuchs.
